Get the Stockscreener App
22.36
7.47%
-1.805
After Hours:
22.32
-0.04
-0.18%
Pharvaris Nv stock is traded at $22.36, with a volume of 151.97K.
It is down -7.47% in the last 24 hours and up +2.99% over the past month.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
See More
Previous Close:
$24.16
Open:
$24.38
24h Volume:
151.97K
Relative Volume:
1.53
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-123.41M
P/E Ratio:
-10.46
EPS:
-2.138
Net Cash Flow:
$-106.93M
1W Performance:
+9.07%
1M Performance:
+2.99%
6M Performance:
+10.80%
1Y Performance:
+30.00%
1-Day Range:
$21.33
$24.50
1-Week Range:
$20.17
$24.52
52-Week Range:
$15.37
$33.00
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
22.36 | 1.21B | 0 | -123.41M | -106.93M | -2.138 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris Reports Q3 2024 Progress and Financials - TipRanks
How To Trade (PHVS) - Stock Traders Daily
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
Trend Tracker for (PHVS) - Stock Traders Daily
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
(PHVS) Proactive Strategies - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
PHVSPharvaris N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at ... - The Hastings Tribune
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - StockTitan
Pharvaris to Host Virtual Investor Event on October 23, 2024 - StockTitan
(PHVS) Investment Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownShould You Sell? - MarketBeat
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at - The Bakersfield Californian
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - StockTitan
Novo Holdings A S Buys 556,970 Shares of Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris N.V.'s SWOT analysis: promising HAE drug boosts stock outlook - Investing.com India
Pharvaris CBO Resigns, Team Absorbs Duties - TipRanks
(PHVS) Technical Data - Stock Traders Daily
Hereditary Angioedema Therapeutics Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $21.09 - MarketBeat
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma - sharewise
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Paradise, NV – Injuries Reported in Vehicle Accident on I-215 W near Las Vegas Blvd Onramp - Local Accident Reports
Las Vegas, NV – Accident on I-215 E near Windmill Ln Results in Injuries - Local Accident Reports
North Las Vegas Man Charged in Fatal Hit-and-Run After Allegedly Fleeing Accident Scene - Hoodline
Paradise, NV – Vehicle Accident at I-215 E and Las Vegas Blvd - Local Accident Reports
Las Vegas, NV – Vehicle Accident at CC215 S and W Sunset Rd Causes Injuries - Local Accident Reports
Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - KRNV
Road closures persist after trucks carrying wood and batteries collide - News3LV
Appeal over identifying invasive hornets in Jersey - BBC.com
Hwy 95 closes in Nye County after crash involving truck carrying lithium batteries - Audacy
1 person transported to hospital after Henderson crash involving bicyclist - Fox 5 Las Vegas
1 hospitalized in Henderson crash involving bicyclistKLAS - KLAS - 8 News Now
Oregon man dies northwest of Las Vegas Valley, state police say - Fox 5 Las Vegas
1 person taken to hospital after crash involving car, bicyclist in Henderson - News3LV
Rep. Steven Horsford releases updated campaign ad after LVPPA concerns - KTNV 13 Action News Las Vegas
Silver Springs man killed in crash on U.S. 50A & 6th Street in Fernley - KTVN
Las Vegas, NV – Collision at CC215 S & W Flamingo Rd Results in Injuries - Local Accident Reports
Pharvaris (NASDAQ:PHVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Pharvaris stock outlook strengthened with price target increase, Outperform rating reiterated by Oppenheimer - Investing.com UK
(PHVS) Technical Pivots with Risk Controls - Stock Traders Daily
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and ... - The Bakersfield Californian
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - StockTitan
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - StockTitan
Pharvaris Presents Data at the Bradykinin Symposium 2024 - StockTitan
Pharvaris to Present at SVB Securities Global Biopharma Conference - Yahoo Finance UK
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):